Table 1.
Demographic and baseline clinical characteristics of the overall study population with moderate-to-severe plaque psoriasis.
| Characteristics | 150 mg (n = 47) | 300 mg (n = 59) |
| Gender | ||
| Male | 21 (44.7) | 47 (79.7) |
| Female | 26 (55.3)∗ | 12 (20.3) |
| Mean age (years) | 39.0 ± 12.4 | 40.0 ± 12.2 |
| BMI (kg/m2) | 22.69 ± 3.14 | 25.64 ± 3.88 |
| Weight (kg) | 61.89 ± 11.06∗ | 76.93 ± 13.67 |
| Psoriasis duration (years) | 16.21 ± 8.43 | 15.23 ± 8.56 |
| Comorbidities | ||
| Metabolic syndrome | 5 (10.6) | 13 (22.0) |
| Hypertension | 4 (9.5) | 12 (21.4) |
| Psoriatic arthritis | 7 (14.9) | 8 (13.6) |
| Hyperuricemia | 2 (4.8) | 8 (14.3) |
| Dyslipidemia | 2 (4.8) | 6 (10.7) |
| Diabetes | 2 (4.8) | 8 (14.3) |
| Coronary heart disease | 1 (2.4) | 3 (5.4) |
| Thyroid papillary carcinoma | 1 (2.4) | 0 |
| IgA nephropathy | 0 | 1 (1.8) |
| Psychiatric disorders | 0 | 1 (1.8) |
| PASI | 14.34 ± 10.04∗ | 20.12 ± 10.84 |
| BSA (%) | 23.27 ± 20.65 | 24.72 ± 20.94 |
| PGA | 2.87 ± 0.88 | 3.40 ± 0.62 |
| Non-biologic systemic therapy | 25 (53.2) | 39 (66.1) |
| Biologics experience | 3 (6.4) | 9 (15.3) |
Data are expressed as mean ± SD or n (%). ∗P < 0.05. BMI: Body mass index; BSA: Body surface area; IgA: Immunoglobulin A; PASI: Psoriasis area and severity index; PGA: Physician global assessment; SD: Standard deviation.